COVID-19 Pneumonia After SARS-CoV-2 Vaccination with CoronaVac: A Case Series from Turkey

被引：2

作者：

Coban, Mehmet Meric ^{[1
]}

Yakar, Mehmet Nuri ^{[2
]}

Kucuk, Murat ^{[3
]}

Ergun, Bisar ^{[3
]}

Celik, Muammer ^{[4
]}

Ergan, Begum ^{[5
]}

Yaka, Erdem ^{[6
]}

Gokmen, Necati ^{[2
]}

机构：

[1] Dokuz Eylul Univ, Fac Med, Dept Internal Med, Izmir, Turkey

[2] Dokuz Eylul Univ, Fac Med, Dept Anaesthesiol & Reanimat, Div Intens Care, Izmir, Turkey

[3] Dokuz Eylul Univ, Fac Med, Dept Internal Med, Div Intens Care, Izmir, Turkey

[4] Dokuz Eylul Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Izmir, Turkey

[5] Dokuz Eylul Univ, Fac Med, Dept Chest Dis, Div Intens Care, Izmir, Turkey

[6] Dokuz Eylul Univ, Fac Med, Dept Neurol, Div Intens Care, Izmir, Turkey

来源：

TURKISH THORACIC JOURNAL | 2022年 / 23卷 / 02期

关键词：

COVID-19; CoronaVac; pneumonia; SARS-CoV-2; vaccination;

D O I：

10.5152/TurkThoracJ.2022.0201

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Coronavirus disease 2019 is a novel viral infection that has caused a pandemic globally. Many kinds of vaccine development studies were conducted to prevent the spread and deaths. The CoronaVac is the most commonly used vaccine in Turkey. Phase 3 trials from various countries revealed that CoronaVac efficacy ranged from 50.7% to 91.25% but increased in moderate or severe cases to 100%. Additionally, it was remarkable owing to high seroconversion rates achieving up to 100%. After the vaccine campaign began in Turkey, critically ill patients continued to admit to our center's intensive care unit though they had been vaccinated with 2 doses of CoronaVac. The clinical course of these patients revealed that they are still at high risk of severe disease and death. Therefore, we aimed to share these patients' clinical characteristics and disease course, laboratory, and radiologic data.

引用

页码：185 / 191

页数：7

共 20 条

[1]

Anadolu Agency, 2021, DELT VAR TURK

[2]

[Anonymous], 2021, SPUTN 5 EM US AUTH

[3]

[Anonymous], 2021, WHO lists additional Covid-19 vaccine for emergency use and issues interim policy recommendations

[4]

Bochnia-Bueno L, 2022, DIAGN MICR INFEC DIS, V102, DOI DOI 10.1016/J.DIAGMICRO-BIO.2021.115597

[5] Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J].

Chen, Nanshan ;

Zhou, Min ;

Dong, Xuan ;

Qu, Jieming ;

Gong, Fengyun ;

Han, Yang ;

Qiu, Yang ;

Wang, Jingli ;

Liu, Ying ;

Wei, Yuan ;

Xia, Jia'an ;

Yu, Ting ;

Zhang, Xinxin ;

Zhang, Li .

LANCET, 2020, 395 (10223) :507-513

[6] Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial [J].

Han, Bihua ;

Song, Yufei ;

Li, Changgui ;

Yang, Wanqi ;

Ma, Qingxia ;

Jiang, Zhiwei ;

Li, Minjie ;

Lian, Xiaojuan ;

Jiao, Wenbin ;

Wang, Lei ;

Shu, Qun ;

Wu, Zhiwei ;

Zhao, Yuliang ;

Li, Qi ;

Gao, Qiang .

LANCET INFECTIOUS DISEASES, 2021, 21 (12) :1645-1653

[7]

Hu J, BIORXIV, DOI [10.1101/2021.07.09.451732, DOI 10.1101/2021.07.09.451732]

[8]

Ilac, 2021, TURK VE TIBB CIH KUR

[9]

Mallapaty Smriti, 2021, Nature, DOI [10.1038/d41586-021-03455-w, 10.1038/d41586-021-00094-z]

[10]

Palacios R., 2021, SSRN ELECT J, DOI [10.2139/SSRN.3822780, 10.2139/ssrn.3822780, DOI 10.2139/SSRN.3822780]

← 1 2 →